drugset / Trial / NCT00343980

Safety and Efficacy of Inhaled Pre-prandial Human Insulin in Type 2 Diabetes

NCT00343980

Phase 3 Terminated 363 enrolled Novo Nordisk A/S
RandomizedParallel-groupOpen-labelTreatment

Summary

This trial is conducted in Asia, Europe and Oceania. The aim of this research study is to compare the efficacy of adding inhaled preprandial insulin to glimepiride compared to adding rosiglitazone to glimepiride for the treatment of type 2 diabetes and to verify its safety (hypoglycaemia, pulmonary function, body weight, insulin antibodies and side effects)

Timeline

Start
2006-10-10
Primary completion
2008-03-10
Completion
2008-03-10

Drugs

EvaluationDrugModalityDoseRoute
Comparator Rosiglitazone Small molecule 4 mg Oral
Subject inhaled human insulin Unknown Inhaled
Background Glimepiride Small molecule 4 mg Oral